Clinical Trial Update: A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating the efficacy and safety of extended-release paliperidone for acute schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone ER (paliperidone)

Snippet

Sponsor: Xian-Janssen Pharmaceutical Ltd. | Conditions: Acute Schizophrenia | Phase 3 | Status: COMPLETED